Comparison of carbamazepine and oxcarbazepine effects on aminothiol levels
| Autor: | Stéphanie Badiou, Philippe Gelisse, Arielle Crespel, Hélène Peyrière, Dominique Hillaire-Buys, Virginie Charasson, Hélène Breton, Jean-Paul Cristol |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Adolescent Homocysteine medicine.drug_class Metabolite medicine.medical_treatment Oxcarbazepine Pharmacology chemistry.chemical_compound Risk Factors medicine Humans Pharmacology (medical) In patient Cysteine Epilepsy Mood stabilizer Dipeptides General Medicine Carbamazepine Middle Aged Anticonvulsant chemistry Cardiovascular Diseases Concomitant Anticonvulsants Female medicine.drug |
| Zdroj: | European Journal of Clinical Pharmacology. 64:83-87 |
| ISSN: | 1432-1041 0031-6970 |
| DOI: | 10.1007/s00228-007-0388-z |
| Popis: | The aim of our study was to investigate the effects of carbamazepine (CBZ) and oxcarbazepine (OXCBZ) on aminothiol levels, including homocysteine (Hcy), cysteine, and cysteinylglycine, in chronically treated patients.Epileptic patients receiving CBZ or OXCBZ were recruited as part of routine clinical practice. Demographic data and concomitant medications were recorded from the patient medical file.Sixty patients were included in the study; 30 patients were treated with CBZ and 30 with OXCBZ. Median Hcy level was significantly higher in CBZ-treated patients (20.6 micromol/l) than in OXCBZ-treated patients (14.0 micromol/l, p0.0001). No correlation was evidenced between antiepileptic drugs or metabolite levels and Hcy levels for each group.Less change observed with OXCBZ compared with CBZ on aminothiol levels could constitute an advantage for OXCBZ treatment in patients with other factors influencing Hcy levels and/or at high risk for cardiovascular diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink